LOWAT

Complexo fitoterápico auxiliar no controle de peso

Complexo
fitoterápico patenteado e seguro de extratos das folhas de Piper
betle e das sementes de Dolichos biflorus, sob a forma
padronizada, respectivamente γ-glutamyl phenyl alanina e ácido gálico que
possui como alvo o tecido.

MECANISMO
DE AÇÃO

LOWAT^® realiza controle
secretório: aumenta em 15% de adiponectina que contribui para diminuir a
gorduraacumulada, e diminui em 17% a de grelina, que auxilia ao
aumentar a saciedade, diminuir a adipogênese, o que reduz a formação e acúmulo
de gordura, promovendo a perda significativa de peso corporal; tudo sob
comprovação científica, além de reduzir os níveis de glicose e triglicerídeos.
Assim, auxilia na perda de peso e IMC em dobro, quando comparado com indivíduos
que realizam apenas atividade física e dieta sem suplementação, funcionando
como regulador secretório que tem como alvo o tecido adiposo, reduzindo a
formação de adipócitos e o acúmulo da gordura, através do estímulo da queima de
gordura. Além de possuir propriedades hepatoprotetora, antioxidante e
anti-inflamatória.

INDICAÇÕES

Redução e controle de
peso, como coadjuvante;

Diminuição de IMC e
da gordura corporal;

Auxiliar no controle
de glicose-diabetes tipo 2 (prevenção de diabetes) e na esteatose hepática;

Manutenção da saúde
cardiovascular; hepatoprotetor;

Prevenção e
coadjuvante no tratamento de síndromes metabólicas.

DOSE USUAL

Recomendação oral 300mg a 900mg de LOWAT^®,
30 minutos antes do almoço e jantar.

SUGESTÃO
DE FÓRMULA

Lowat^® (P. betle-folha / D. biflorus-sementes)
…………..300mg

Modo de uso: 1 dose,3 vezes ao
dia, 30 minutosantes das refeições.

Indicação: controle do peso e diminuição do IMC.

ESTUDOS CLÍNICOS

Efficacy of an herbal formulation LI10903F
containing Dolichos biflorus and Piper betle extracts on weight
management

Background A novel herbal formulation LI10903F, alternatively known as
LOWAT® was developed based on its ability to inhibit adipogenesis and
lipogenesis in 3T3-L1 adipocytes model. The clinical efficacy and tolerability
of LI10903F were evaluated in an eight-week, randomized, double-blind,
placebo-controlled, clinical trial in 50 human subjects with body mass index
(BMI) between 30 and 40 kg/m² (clinical trial registration number:
ISRCTN37381706). Participants were randomly assigned to either a placebo or
LI10903F group. Subjects in the LI10903F group received 300 mg of herbal
formulation thrice daily, while subjects in the placebo group received 300 mg
of placebo capsules thrice daily. All subjects were provided a standard diet
(2,000 kcal daily) and participated in a moderate exercise of 30 min walk for
five days a week. Additionally, the safety of this herbal formulation was
evaluated by a series of acute, sub-acute toxicity and genotoxicity studies in
animals and cellular models. Results After eight weeks of supplementation,
statistically significant net reductions in body weight (2.49 kg; p=0.00005)
and BMI (0.96 kg/m²; p=0.00004) were observed in the LI10903F group
versus placebo group. Additionally, significant increase in serum adiponectin
concentration (p=0.0076) and significant decrease in serum ghrelin
concentration (p=0.0066) were found in LI10903F group compared to placebo
group. Adverse events were mild and were equally distributed between the two
groups. Interestingly, LI10903F showed broad spectrum safety in a series of
acute, sub-acute toxicity and genotoxicity studies. Conclusions Results from
the current research suggest that LI10903F or LOWAT is well-tolerated, safe and
effective for weight management.

Efficacy of Lowat – a natural weight management herbal formulation in
obese human subjects

We investigated the efficacy and safety of LOWAT a novel herbal weight
management formula comprising of extracts Piper betle and Dolichos
biflorus. In a randomized, double-blind, placebo-controlled study, subjects
(n=25) received 900 mg/day of LOWAT for 8 weeks and maintained a standard 2000
calorie daily diet. Body weight, BMI, clinical chemistry and hematological
parameters, urine analysis and biochemical markers: adiponectin and ghrelin
were measured at baseline and weeks 2, 4 and 8 of treatment. After week 2,
subjects lost 1.41 kg of their mean body weight compared to 0.79 kg reduction
in placebo group while BMI reduction was 0.534 kg/m² compared to
placebo (0.309 kg/m²). After week 8, LOWAT group exhibited a
significant 2.4 fold (140%) body weight reduction (p<0.05). BMI was reduced
by 2.4 fold (136%) compared to placebo (p<0.05). Serum adiponectin
significantly increased 15.3% (p<0.05) and serum ghrelin significantly decreased
by 17.3% (p<0.05) compared to placebo. These results are further
substantiated by an in vivo study in which LOWAT significantly reduced
body weight gain and increased serum adiponectin level in rats on a high fat
diet as compared to control. Minor adverse events reported by subjects were not
treatment related. The safety of LOWAT was further established by a series of
acute and sub-acute toxicity studies in animals. This study further proves the
efficacy of LOWAT in reducing body weight and BMI and improving key biochemical
parameters of obesity in obese subjects.

Efficacy and Safety Evaluation of a Novel Weight Management Herbal
Formulation LOWAT

Overweight and obesity have become a global
health concern. Therefore, it is essential to develop effective and safe
therapeutics for weight management. To achieve this, 480 herbal extracts were
screened for their adipogenesis inhibitory activities. Extracts from Piper
betle and Dolichos biflorus exhibiting potent anti-adipogenic potentials were
chosen for further analysis. The synergistic anti-adipogenic effects of the two
extracts were assessed by combining the individual extracts at various ratios
to create a proprietary formulation LOWAT which was significantly better than
the individual extracts in terms of adipogenic inhibition. In vitro studies
showed that LOWAT inhibited pre-adipocyte differentiation and potentiated lipid
breakdown in mature adipocytes. In vivo studies indicated that LOWAT
significantly reduced body weight gain while increased serum adiponectin level
in rats on a high fat diet as compared to the control rats. Adiponectin is
secreted from adipose tissue into the bloodstream and the level is inversely
correlated with body fat percentage. Toxicological studies on LOWAT
demonstrated that acute oral and acute dermal LD50 were greater than 5.0 g/kg and 2.0 g/kg, respectively. Primary eye irritation study
showed that the LOWAT was mildly irritating to the eye. No toxicity was
observed in primary skin irritation test. Repeated dose 28-day subchronic oral toxicity
test revealed no toxic effects on biochemical or clinical parameters. The no-observable-adverse-effect-level (NOAEL) for LOWAT in male and
female Sprague-Dawley rats was concluded to be at least 2.5 g/kg body weight.
Results suggest that this formulation may be an effective weight management
agent.

Dolichos biflorus Linn. ameliorates
diabetic complications in streptozotocin induced diabetic rats

BACKGROUND:Horsegram (Dolichos biflorus Linn.) is a known
antilithiatic, hypolipedemic and has free radical scavenging activity and
increased production of reactive oxygen species play a role in
pathophysiological mechanisms that trigger diabetic complications. AIM: To see
the effect of daily oral feeding of D.biflorous on nephropathy and
retinopathy in streptozotocin (STZ) induced-diabetic rats. Materials and
methods:A total of 24 healthy rats were randomly grouped into controls,
diabetic and diabetic on Dolichos. Diabetes was induced by a single dose
of STZ (55 mg/kg) and animals were given prepared food and water ad libitum. Dolichos
was orally given at 300 mg/kg/day to rats in diabetic on Dolichos group
for next 30 days. Fasting blood glucose levels was monitored at beginning and
at the end of the experiment while assessment of serum creatinine levels and
histopathological study of kidney and retina was carried only at the end of the
experiment. Statistical differences between groups were analyzed using analysis
of variance followed by, Bonferroni test as posthoc test.RESULTS:Results
indicated improvement in serum creatinine levels and reduced glomerular
sclerosing and Bowman’s space with interstitial alterations and significantly
reduced renal hypertrophy in diabetic rat son Dolichos diabetic rats (P
< 0.001). Retinal layers showed inconsistent improvement in the width of the
neuronal layers and decreased vacuolization of plexiform layers and retinal
vessel density. Conclusion:D. biflorus at doses of 300 mg/kg/day for 30
days resulted in gradual but significant decreased diabetic nephropathy.

Reduction of oxidative stress by an ethanolic
extract of leaves of Piper betle (Paan) Linn. decreased
methotrexate-induced toxicity

Methotrexate (MTX), a folate antagonist, is currently used as first line
therapy for autoimmune diseases like rheumatoid arthritis and psoriasis, but
its use is limited by the associated hepatotoxicity. As leaves of Piper
betle, belonging to family Piperaceae, have antioxidant and
anti-inflammatory properties, the present study was undertaken to investigate
the potential of Piper betle leaf extract (PB) in attenuating
MTX-induced hepatotoxicity. Rats pre-treated with PB (50 or 100 mg kg(-1) b.w.,
p.o.) were administered with a single dose of MTX (20 mg kg(-1), b.w., i.p.)
and its hepatoprotective efficacy was compared with folic acid (1 mg kg(-1)
b.w., i.p.), conventionally used to minimize MTX-induced toxicity. MTX-induced
hepatotoxicity was confirmed by increased activities of marker enzymes, alanine
transaminase, aspartate transaminase, and alkaline phosphatase which were
remitted by pre-treatment with PB and corroborated with histopathology.
Additionally, MTX-induced hepatic oxidative stress which included increased
generation of reactive oxygen species, enhanced lipid peroxidation, depleted
levels of glutathione and decreased activities of antioxidant enzymes was
effectively mitigated by PB, indicative that its promising antioxidant-mediated
hepatoprotective activity was worthy of future pharmacological consideration.

REFERÊNCIAS

BATISTUZZO, J. A O; ITAYA, M.; ETO, Y. Formulário
Médico-Farmacêutico. 4 ed. São Paulo: Pharmabooks, 2011.

SENGUPTA K.; MISHRA A.T.; RAO M.K.; SARMA K.; KRISHNARAJU A.V.; TRIMURTULU G. Efficacy of an
herbal formulation LI10903F containing Dolichos biflorus and Piper
betle extracts on weight management. Lipids Health Dis. V.11, nº 176. 2012.
Disponível em:< http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551693/>. Acesso em: 16 de Novembro de 2015, às 11:05.

BAGCHI D.; LAU F. C.; GOLAKOTI, T; KRISHNARAJU, A.V.; SENGUPTA, K.
Efficavy of Lowat- a natural weight management herbal formulation in obese
human subjects. Disponível em:<
http://www.fasebj.org/cgi/content/meeting_abstract/25/1_MeetingAbstracts/601.10>.
Acesso em: 04 de Janeiro de 2016, às 14:05.

CHATTERJEE A.;
FERNANDES, C.; KHANDAJAVALA, B.; GOLAKOTI, T.; KRISHNARAJU, A.V.; SENGUPTA, K.;
LAU, F. C.; BAGCHI, D. Efficacy and Safety Evaluation of a Novel Weight
Management Herbal Formulation Lowat. Disponível em:< https://www.gorealdose.com/common/info/research/Dolichos-Betel-Chatterjee-Color-Poster.pdf>.
Acesso em: 04 de Janeiro de 2016, às 15:05

SAXENA, Y. et. al. Dolichos biflorus Linn. ameliorates diabetic complications in
streptozotocin induced diabetic rats. Ayu. V. 35, n.4, p. 442-446, Oct-Dec 2014. Disponível em:< http://www.ncbi.nlm.nih.gov/pubmed/26195910>. Acesso em: 06 de
janeiro de 2016, às 14:19.

DE, S.; SEN, T.; CHATTERJEE, M. Reduction of oxidative stress by an ethanolic extract of leaves of Piper
betle (Paan) Linn. decreased methotrexate-induced toxicity. Mol Cell Biochem. V. 409, n. 1-2, p. 191-197, Nov 2015.
Disponível em:< http://www.ncbi.nlm.nih.gov/pubmed/26276309>. Acesso em: 06 de
janeiro de 2016, às 14:25.